Daxor Corporation to Showcase the Benefits of BVA-100® Guided Care at the American Association of Heart Failure Nurses (AAHFN) 19th Annual Meeting
Oak Ridge, TN, June 20, 2023 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it will exhibit at the American Association of Heart Failure Nurses (AAHFN) 19th Annual Meeting from June 29 – July 1, 2023 at the Boston Marriott Copley Place.
“The AAHFN Annual Meeting is an exciting opportunity to generate awareness and educate nurses and other health professionals interested in heart failure on the use of our blood volume technology. Our diagnostic has been proven to reduce heart failure 30-day mortality by 82% and 30-day readmissions by 56%, and results in a 55% reduction in length of stay when done on admission,” said Kathryn Kornafel, VP, Marketing and Commercial Development.
Daxor will also be sponsoring a focus group hosted by Dr. Robin J. Trupp, Ph.D., MSN, FHSA, FAHA, founding member and former President of AAHFN, to allow nurses from across the continuum of practice to discuss openly and learn from each other their experiences and the benefits of blood volume analysis.
The AAHFN is a specialty organization dedicated to advancing nursing education, clinical practice, and research to improve heart failure patient outcomes. The company will be exhibiting at Booth 275. Register for the event HERE.
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor’s mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
